Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein

Lung resistance-related protein (LRP) overexpression in leukaemic blast cells from acute leukaemia patients and the effect of LRP or P-glycoprotein (P-gp) on the clinical outcome of acute leukaemia were investigated individually by dividing patients into four groups. The complete remission rate of group I (LRP and P-gp both negative) was 81·7%, group II (only LRP positive) 87·5%, group III (only P-gp positive) 87·1% and group IV (LRP and P-gp both positive) 40·0%. There were no statistical differences between group I and groups II or III, but a significant difference was observed between groups I, II or III and group IV. Median overall survival in group IV was significantly shorter (4·6 months) than in groups I, II or III, although no significant differences were observed between group I and groups II or III (18·9, 20·5 and 31·8 months). There was a tendency for disease-free survival in group III to be longer than that in groups I, II or IV. The reasons for these findings are discussed. Our present results indicate that the co-existence of LRP and P-gp strongly influenced the effectiveness of induction chemotherapy and long-term prognosis, whereas the isolated presence of LRP or P-gp did not.